Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Non-Current Liabilities (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Total Non-Current Liabilities data on record, last reported at $157.2 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 129.67% year-over-year to $157.2 million; the TTM value through Dec 2025 reached $157.2 million, up 129.67%, while the annual FY2025 figure was $157.2 million, 129.67% up from the prior year.
  • Total Non-Current Liabilities reached $157.2 million in Q4 2025 per VRDN's latest filing, up from $71.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $157.2 million in Q4 2025 and bottomed at -$606.4 million in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $12.8 million, with a median of $37.0 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: soared 162.8% in 2022, then tumbled 1391.36% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $14.8 million in 2021, then skyrocketed by 162.8% to $38.9 million in 2022, then increased by 22.03% to $47.4 million in 2023, then soared by 44.38% to $68.5 million in 2024, then surged by 129.67% to $157.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $157.2 million in Q4 2025, $71.6 million in Q3 2025, and $65.1 million in Q2 2025.